Health Care·Biotechnology·$5.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.45 | N/A | -15.38% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.45 | N/A | -15.38% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concern about the current performance while maintaining a focus on future growth strategies.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term strategies despite current setbacks.
CG Oncology's first-quarter results indicate ongoing challenges, particularly reflected in the EPS miss. The stock's 3.9% decline suggests investor disappointment. Without revenue figures or guidance, uncertainty remains about the company's short-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FOX CORP Class A
May 12, 2025